{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:07:03Z","timestamp":1792469223173,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"crossref","award":["Skin and Melanoma Service Grant"],"award-info":[{"award-number":["Skin and Melanoma Service Grant"]}],"id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11764-019-00770-0","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T09:32:13Z","timestamp":1559640733000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors"],"prefix":"10.1007","volume":"13","author":[{"given":"Julia","family":"Lai-Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kortnye","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Lisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-7807","authenticated-orcid":false,"given":"Michael","family":"Jefford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"issue":"36","key":"770_CR1","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"Charles M. Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"Journal of Clinical Oncology"},{"key":"770_CR2","doi-asserted-by":"crossref","unstructured":"Long GV, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2017:Jco2017741025.","DOI":"10.1200\/JCO.2017.74.1025"},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"Dirk Schadendorf","year":"2017","unstructured":"Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017;82:45\u201355.","journal-title":"European Journal of Cancer"},{"issue":"9","key":"770_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, et al. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360.","journal-title":"Lancet Oncol"},{"key":"770_CR5","doi-asserted-by":"crossref","unstructured":"Hodi, S.F., et al., Durable, long-term survival in previously treated patients with advanced melanoma who received nivolumab monotherapy in a phase I trial. Presented at the 2016 AACR Annual Meeting; April 16-20, New Orleans Louisiana. Abstract CT001, 2016.","DOI":"10.1158\/1538-7445.AM2016-CT001"},{"key":"770_CR6","unstructured":"Robert, C., et al., Long-term outcomes in patients (Pts) with advanced melanoma treated with pembrolizumab (Pembro): 4-year overall survival (OS) results from KEYNOTE-001, in 7th European Post-Chicago Melanoma\/Skin Cancer Meeting. 2017: Munich."},{"issue":"4","key":"770_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","volume":"36","author":"Margaret K. Callahan","year":"2018","unstructured":"Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391\u20138.","journal-title":"Journal of Clinical Oncology"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","volume":"67","author":"Dirk Schadendorf","year":"2016","unstructured":"Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46\u201354.","journal-title":"European Journal of Cancer"},{"issue":"1","key":"770_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1477-7525-10-66","volume":"10","author":"Dennis A Revicki","year":"2012","unstructured":"Revicki DA, van den Eertwegh AJM, Lorigan P, Lebbe C, Linette G, Ottensmeier CH, et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes. 2012;10(1):66\u20136.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"10","key":"770_CR10","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","volume":"27","author":"G. V. Long","year":"2016","unstructured":"Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, et al. Effect of nivolumab on health-related quality of life in patients with treatment-na\u00efve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol. 2016;27(10):1940\u20136.","journal-title":"Annals of Oncology"},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","volume":"82","author":"Dirk Schadendorf","year":"2017","unstructured":"Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80\u201391.","journal-title":"European Journal of Cancer"},{"issue":"13","key":"770_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389\u201398.","journal-title":"Lancet Oncol"},{"issue":"7","key":"770_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","volume":"51","author":"Dirk Schadendorf","year":"2015","unstructured":"Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer (Oxford, England : 1990). 2015;51(7):833\u201340.","journal-title":"European Journal of Cancer"},{"issue":"2","key":"770_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CMR.0b013e32835e5932","volume":"23","author":"JB Winstanley","year":"2013","unstructured":"Winstanley JB, White EG, Boyle FM, Thompson JF. What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. Melanoma Res. 2013;23(2):167\u201374.","journal-title":"Melanoma Res"},{"key":"770_CR15","doi-asserted-by":"crossref","unstructured":"Rogiers, A., et al., Psychosocial outcome and health related quality of life (HRQoL) in advanced melanoma survivors, in 2018 ASCO Cancer Survivorship Symposium. 2018: Orlando, Florida, USA.","DOI":"10.1200\/JCO.2018.36.7_suppl.162"},{"issue":"17","key":"770_CR16","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1200\/JCO.2017.76.2146","volume":"36","author":"JS Temel","year":"2018","unstructured":"Temel JS, Gainor JF, Sullivan RJ, Greer JA. Keeping expectations in check with immune checkpoint inhibitors. J Clin Oncol. 2018;36(17):1654\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"770_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"F. Stephen Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott D, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"770_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u201333.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"770_CR19","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2016.34.15_suppl.9503","volume":"34","author":"Caroline Robert","year":"2016","unstructured":"Robert, C., Ribas A., Hamid O., Daud A., Wolchok J.D., Joshua A.M., Hwu W.J., Weber J.S., Gangadhar T.C., Joseph R.W., Dronca R.S., Patnaik A., Zarour H.M., Kefford R., Hersey P., Li X., Diede S.J., Ebbinghaus S., Hodi F.S., Three year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol, 2016. 34(suppl: abstr 9503), 9503.","journal-title":"Journal of Clinical Oncology"},{"issue":"9839","key":"770_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"Axel Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"The Lancet"},{"issue":"10105","key":"770_CR21","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"Jacob Schachter","year":"2017","unstructured":"Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 10105;390:1853\u201362.","journal-title":"The Lancet"},{"key":"770_CR22","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","DOI":"10.1093\/jnci\/85.5.365"},{"issue":"10","key":"770_CR23","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/cncr.23424","volume":"112","author":"Janice N. Cormier","year":"2008","unstructured":"Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008;112(10):2249\u201357.","journal-title":"Cancer"},{"issue":"1","key":"770_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0000000000000122","volume":"25","author":"Julie B. Winstanley","year":"2015","unstructured":"Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, et al. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module. Melanoma Res. 2015;25(1):47\u201358.","journal-title":"Melanoma Research"},{"issue":"1","key":"770_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/pon.1705","volume":"20","author":"P Wright","year":"2011","unstructured":"Wright P, Smith AB, Keding A, Velikova G. The Social Difficulties Inventory (SDI): development of subscales and scoring guidance for staff. Psychooncology. 2011;20(1):36\u201343.","journal-title":"Psychooncology"},{"issue":"10","key":"770_CR26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/pon.2016","volume":"21","author":"P Schofield","year":"2012","unstructured":"Schofield P, Gough K, Lotfi-Jam K, Aranda S. Validation of the Supportive Care Needs Survey-short form 34 with a simplified response format in men with prostate cancer. Psychooncology. 2012;21(10):1107\u201312.","journal-title":"Psychooncology"},{"key":"770_CR27","doi-asserted-by":"crossref","unstructured":"Levy D, et al. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer. 2018.","DOI":"10.1007\/s00520-018-4443-3"},{"key":"770_CR28","doi-asserted-by":"crossref","unstructured":"Dunn, J., et al., Systematic review of psychosocial outcomes for patients with advanced melanoma. Psycho-Oncology, 2016: p. n\/a-n\/a.","DOI":"10.1002\/pon.4290"},{"issue":"14","key":"770_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"770_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pon.3022","volume":"22","author":"L Koch","year":"2013","unstructured":"Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (>\/= 5 years) cancer survivors--a systematic review of quantitative studies. Psychooncology. 2013;22(1):1\u201311.","journal-title":"Psychooncology"},{"issue":"36","key":"770_CR31","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","volume":"34","author":"Mbathio Dieng","year":"2016","unstructured":"Dieng M, Butow PN, Costa DSJ, Morton RL, Menzies SW, Mireskandari S, et al. Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial. J Clin Oncol. 2016;34(36):4405\u201314.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"770_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/pon.955","volume":"15","author":"GT Deimling","year":"2006","unstructured":"Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15(4):306\u201320.","journal-title":"Psychooncology"},{"key":"770_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lungcan.2016.08.002","volume":"100","author":"Joshua M. Bauml","year":"2016","unstructured":"Bauml JMMD, et al. Scan-associated distress in lung cancer: quantifying the impact of \u201cscanxiety\u201d. Lung Cancer. 2016;100:110\u20133.","journal-title":"Lung Cancer"},{"issue":"2","key":"770_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153\u201365.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"770_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","volume":"34","author":"KR Yabroff","year":"2016","unstructured":"Yabroff KR, Dowling EC, Guy GP Jr, Banegas MP, Davidoff A, Han X, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34(3):259\u201367.","journal-title":"J Clin Oncol"},{"key":"770_CR36","first-page":"2","volume":"41","author":"CL Paul","year":"2017","unstructured":"Paul CL, et al. Impact of financial costs of cancer on patients \u2013 the Australian experience. Cancer Forum. 2017;41:2.","journal-title":"Cancer Forum"},{"issue":"10","key":"770_CR37","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/bjc.2014.505","volume":"111","author":"ME Brennan","year":"2014","unstructured":"Brennan ME, Gormally JF, Butow P, Boyle FM, Spillane AJ. Survivorship care plans in cancer: a systematic review of care plan outcomes. Br J Cancer. 2014;111(10):1899\u2013908.","journal-title":"Br J Cancer"},{"issue":"7","key":"770_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/cncr.28884","volume":"121","author":"Deborah K. Mayer","year":"2014","unstructured":"Mayer, D.K., et al., Summing it up: an integrative review of studies of cancer survivorship care plans (2006-2013). Cancer, 2015. 121(7): 978\u2013996.","journal-title":"Cancer"},{"key":"770_CR39","first-page":"534","volume-title":"From cancer patient to cancer survivor: lost in transition","author":"Institute of Medicine and the National Research Council","year":"2006","unstructured":"Institute of Medicine and the National Research Council. In: Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006. p. 534."},{"key":"770_CR40","unstructured":"American Society of Clinical Oncology, American Society of Clinical Oncology Clinical Practice Survivorship Guidelines and Adaptations. 2014 [cited 2018 7 July]; Available from: www.asco.org\/guidelines\/survivorship ."},{"issue":"2","key":"770_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/tbj.12374","volume":"21","author":"M Mayer","year":"2015","unstructured":"Mayer M, et al. Symptom burden and quality of life among women with HER2(+) metastatic breast cancer. Breast J. 2015;21(2):208\u201310.","journal-title":"Breast J"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-019-00770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11764-019-00770-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-019-00770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T09:15:34Z","timestamp":1663578934000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11764-019-00770-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s11764-019-00770-0","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CK has received travel assistance from Roche. DM has received honoraria and consultancy fees from Bristol-Myers Squibb, MSD and Novartis, and institutional research funding from Merck. SS has received honoraria and consultancy fees from Bristol-Myers Squibb and Merck. MJ has received travel assistance from Roche. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}